vs

Side-by-side financial comparison of Lucas GC Ltd (LGCL) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.

Lucas GC Ltd is the larger business by last-quarter revenue ($7.5M vs $7.0M, roughly 1.1× Relay Therapeutics, Inc.).

Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.

LGCL vs RLAY — Head-to-Head

Bigger by revenue
LGCL
LGCL
1.1× larger
LGCL
$7.5M
$7.0M
RLAY

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
LGCL
LGCL
RLAY
RLAY
Revenue
$7.5M
$7.0M
Net Profit
$414.1K
Gross Margin
33.7%
Operating Margin
4.0%
Net Margin
5.6%
Revenue YoY
Net Profit YoY
EPS (diluted)
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LGCL
LGCL
RLAY
RLAY
Q4 25
$7.0M
Q3 25
$0
Q2 25
$7.5M
Q1 25
$7.7M
Q4 24
$0
Q3 24
$0
Q2 24
$11.5M
$0
Q1 24
$10.0M
Net Profit
LGCL
LGCL
RLAY
RLAY
Q4 25
Q3 25
$-74.1M
Q2 25
$414.1K
Q1 25
$-77.1M
Q4 24
Q3 24
$-88.1M
Q2 24
$1.0M
$-92.2M
Q1 24
$-81.4M
Gross Margin
LGCL
LGCL
RLAY
RLAY
Q4 25
Q3 25
Q2 25
33.7%
Q1 25
Q4 24
Q3 24
Q2 24
33.5%
Q1 24
Operating Margin
LGCL
LGCL
RLAY
RLAY
Q4 25
Q3 25
Q2 25
4.0%
Q1 25
-1105.2%
Q4 24
Q3 24
Q2 24
8.8%
Q1 24
-903.0%
Net Margin
LGCL
LGCL
RLAY
RLAY
Q4 25
Q3 25
Q2 25
5.6%
Q1 25
-1003.6%
Q4 24
Q3 24
Q2 24
8.9%
Q1 24
-813.3%
EPS (diluted)
LGCL
LGCL
RLAY
RLAY
Q4 25
Q3 25
$-0.43
Q2 25
$0.20
Q1 25
$-0.46
Q4 24
Q3 24
$-0.63
Q2 24
$0.01
$-0.69
Q1 24
$-0.62

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LGCL
LGCL
RLAY
RLAY
Cash + ST InvestmentsLiquidity on hand
$606.9K
$84.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.3M
$567.1M
Total Assets
$8.8M
$621.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LGCL
LGCL
RLAY
RLAY
Q4 25
$84.0M
Q3 25
$91.6M
Q2 25
$606.9K
Q1 25
$93.5M
Q4 24
$124.3M
Q3 24
$152.4M
Q2 24
$978.1K
$134.1M
Q1 24
$152.9M
Stockholders' Equity
LGCL
LGCL
RLAY
RLAY
Q4 25
$567.1M
Q3 25
$607.7M
Q2 25
$6.3M
Q1 25
$721.1M
Q4 24
$777.8M
Q3 24
$838.9M
Q2 24
$5.3M
$681.7M
Q1 24
$745.8M
Total Assets
LGCL
LGCL
RLAY
RLAY
Q4 25
$621.3M
Q3 25
$670.0M
Q2 25
$8.8M
Q1 25
$799.4M
Q4 24
$871.3M
Q3 24
$930.1M
Q2 24
$7.8M
$772.5M
Q1 24
$841.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LGCL
LGCL
RLAY
RLAY
Operating Cash FlowLast quarter
$-235.5M
Free Cash FlowOCF − Capex
$-235.9M
FCF MarginFCF / Revenue
-3370.0%
Capex IntensityCapex / Revenue
5.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-622.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LGCL
LGCL
RLAY
RLAY
Q4 25
$-235.5M
Q3 25
$-62.1M
Q2 25
Q1 25
$-73.2M
Q4 24
$-249.1M
Q3 24
$-75.1M
Q2 24
$-65.8M
Q1 24
$-50.3M
Free Cash Flow
LGCL
LGCL
RLAY
RLAY
Q4 25
$-235.9M
Q3 25
$-62.1M
Q2 25
Q1 25
$-73.6M
Q4 24
$-251.1M
Q3 24
$-75.3M
Q2 24
$-65.8M
Q1 24
$-52.1M
FCF Margin
LGCL
LGCL
RLAY
RLAY
Q4 25
-3370.0%
Q3 25
Q2 25
Q1 25
-958.4%
Q4 24
Q3 24
Q2 24
Q1 24
-520.7%
Capex Intensity
LGCL
LGCL
RLAY
RLAY
Q4 25
5.9%
Q3 25
Q2 25
Q1 25
5.0%
Q4 24
Q3 24
Q2 24
Q1 24
17.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LGCL
LGCL

Recruitment service$4.4M60%
Others$2.9M39%

RLAY
RLAY

Segment breakdown not available.

Related Comparisons